small integral membrane protein 10 like 2BGenealiases: LINC00087 · NCRNA00087
Q-omics provides the consensus-scored SMIM10L2B profile across patient tissues and cancer cell-line models. SMIM10L2B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SMIM10L2B is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, SMIM10L2B RNA expression shows 22,423 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, KIRC, and GBM as cancer lineages where SMIM10L2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMIM10L2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMIM10L2B survival associations across molecular data types. SMIM10L2B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMIM10L2B RNA expression–survival associations across cancer types. High SMIM10L2B expression shows unfavorable associations in STAD, but favorable associations in UVM, ACC, KIRC, LGG and MESO. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SMIM10L2B RNA expression.
This table summarizes SMIM10L2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SMIM10L2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMIM10L2B shows lower tumor expression in KIRC, THCA, KIRP, LUAD, COAD and UCEC. The KIRC box plot shows higher SMIM10L2B RNA expression in normal versus tumor tissue (log2 FC = −1.839, t-test p < 0.001).
This table shows molecular features associated with SMIM10L2B in patient tissues and cancer cell lines. In patient samples, SMIM10L2B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SMIM10L2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia.
